Julphar wraps up participation at regional debut of leading global pharma event

MENA pharma market set to top $44bln

Julphar wraps up participation at regional debut of leading global pharma event

Event attended by 250 exhibitors and 4,000 industry professionals from around the world

Ras Al Khaimah (UAE) – Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, witnessed strong footfall at the regional debut of the leading global pharmaceutical exhibition, CPhI, in Abu Dhabi, which attracted 250 exhibitors and 4,000 industry professionals.

His Excellency Sheikh Nahyan bin Mubarak al Nahyan, the UAE Minister of Tolerance, officially inaugurated the exhibition before being personally escorted to Julphar’s stand by the company’s General Manager, Jerome Carle. The event took place at the Abu Dhabi National Exhibition Centre (ADNEC) from 3-5 September 2018 and attracted visitors from across the globe from countries including India, Turkey, Korea, Japan and China.

CPhI is the region’s leading platform bringing together pharma ingredients, product manufacturers, suppliers and buyers covering every step of the pharma supply chain from drug research and discovery to finished dosage. The exhibition is designed to increase partnerships and business opportunities on both a local and international level, which will in turn help to increase the value of the MENA pharma market to more than AED 162 billion ($44bn) by 2020.

Speaking at the event, Carle said: "CPhI Middle East and Africa 2018 formed the perfect backdrop for key players in the regional pharmaceutical sector and beyond to congregate, connect, share and ideate. Having events of this caliber in the region and in the UAE, which spotlight the local pharma landscape, will undoubtedly go a long way towards boosting the sector.

“We felt the positive impact of the event from day one with very strong footfall and interest in our company. We had senior representatives on the ground from our business development, consumer, diabetes, R&D, procurement and supply chain departments, who took full advantage of the myriad opportunities to meet with potential business partners and industry leaders from all over the world."

Hot topics of discussion at CPhI included the key drivers behind the MEA pharma market, including the growth of the population, greater investment and spending in healthcare from governments, western lifestyle influence on health such as obesity and chronic diseases including diabetes, cardiovascular disease and oncology.

“One of the most eagerly anticipated sessions featured Dr Amin Hussein Amiri, Asst. Undersecretary of Public Health Policy and Licensing, Ministry of Health and Prevention, UAE, in a discussion about the UAE pharmaceutical sector, which was well received by a packed audience of industry professionals” said Cara Turner, Brand Director, CPhI Middle East & Africa.

Carle added that there had been a shift in perceptions over the past few years with regards to generics and that people were starting to take more of an interest in Julphar and its products.

He said: “As the national pharmaceutical company and one of the largest pharmaceutical manufacturers in the region, Julphar is part of the fabric of the UAE and we are committed to providing affordable healthcare solutions to families and supporting the growth of the sector.

“Following a strong double digit sales growth, we have increased our market share in the UAE to reach the number 1 position. We believe we are now at an inflection point that will allow us to take full advantage of the new opportunities to innovate, grow our pipeline and better serve consumers.

“Thanks to events like CPhI, Julphar now has a unique opportunity to establish itself as a major force in the regional pharmaceutical market.”


About Julphar

Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to more than 50 countries on five continents.

Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicines a day. In 2012, Julphar became one of the largest producers of insulin in the world.

For more information, visit www.julphar.net

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market.

CPhI hosts events in Europe, North America, Korea, China, India, Japan, Southeast Asia and the Middle East, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.

 For more information visit: www.cphi.com

© Press Release 2018

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases